Proactive Investors - Run By Investors For Investors

Pressure BioSciences closes first tranche of offer

Pressure cycling technology provider Pressure BioSciences closed the first tranche of the over-subscription amount of its $5mln private placement
Pressure BioSciences closes first tranche of offer
Oversubscribed deal

Pressure cycling technology provider to the life science industry Pressure BioSciences (OTCMKTS:PBIO), said on Tuesday it has closed the first tranche of the over-subscription amount of its $5mln Private Placement.

This follows the receipt of $550,000 in gross proceeds from the sixth overall closing of the offering. This closing increased the total amount raised in the offering to $5.56mln.

The initial terms of the offering limited the amount that could be raised to $6.25mln ($5mln plus a $1.25mln over-subscription amount). 

The Company recently approved an increase in the over-subscription amount to $2.5mln, which increased the capacity of the offering to a maximum of $7.5mln.  Following the sixth closing, $1.94mln remains available in the offering.

The company will issue senior secured convertible debentures with a fixed conversion price of $0.28 per restricted common share, and common stock purchase warrants exercisable into shares of restricted common stock at an exercise price of $0.40 per share.

On Tuesday, Pressure BioSciences shares were up 5.4% at $0.35.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

November 15 2018
The goal of the program is to extend the visualization extracted from 2D ultrasound images and visualize 4D images
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
May 14 2018
Physiomics' share price surged on a €500,000 contract for its virtual tumour software with Merck KgaA.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use